Get the Stockscreener App
0.00
100.00%
-2.05
Aadi Bioscience Inc stock is traded at $0.00, with a volume of 0.
It is down -100.00% in the last 24 hours and down -100.00% over the past month.
Aadi Bioscience Inc is a clinical-stage biopharmaceutical company developing precision therapies for genetically-defined cancers. Aadi's primary goal is to bring transformational therapies to cancer patients with mTOR pathway driver alterations such as alterations in TSC1 or TSC2 genes, where other mTOR inhibitors have not or cannot be effectively exploited due to problems of pharmacology, effective drug delivery, safety, or effective targeting to the disease site. It has one operating segment, which is the business of developing and commercializing proprietary therapeutic. Geographically, it is located in the United States.
See More
Previous Close:
$2.05
Open:
$0
24h Volume:
0
Relative Volume:
0.00
Market Cap:
$94.89M
Revenue:
$23.26M
Net Income/Loss:
$-63.41M
P/E Ratio:
0.00
EPS:
-2.36
Net Cash Flow:
$-64.56M
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
-100.00%
1-Day Range:
$0.00
$0.00
1-Week Range:
$0.00
$0.00
52-Week Range:
$0.00
$3.812
Aadi Bioscience Inc Stock (AADI) Company Profile
Name
Aadi Bioscience Inc
Sector
Industry
Phone
424-473-8055
Address
17383 SUNSET AVENUE, PACIFIC PALISADES
Compare AADI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AADI
Aadi Bioscience Inc
|
0.00 | 94.89M | 23.26M | -63.41M | -64.56M | -2.36 |
|
ONC
Beigene Ltd Adr
|
241.43 | 27.03B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
436.00 | 112.64B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.335 | 40.86M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
588.34 | 64.17B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
75.06 | 6.07B | 0 | -153.72M | -103.81M | -2.00 |
Aadi Bioscience Inc Stock (AADI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-27-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| Aug-21-24 | Downgrade | Jefferies | Buy → Hold |
| Aug-21-24 | Downgrade | TD Cowen | Buy → Hold |
| Dec-15-23 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jan-11-22 | Initiated | Jefferies | Buy |
| Oct-01-21 | Initiated | Cowen | Outperform |
| Sep-14-21 | Initiated | Ladenburg Thalmann | Buy |
| Sep-08-21 | Initiated | Piper Sandler | Overweight |
View All
Aadi Bioscience Inc Stock (AADI) Latest News
Reviewing Aadi Bioscience (NASDAQ:AADI) & UCB (OTCMKTS:UCBJF) - Defense World
Whitehawk Therapeutics Reports Strong Q1 2025 Results - TipRanks
Whitehawk Reports First Quarter 2025 Financial Results and Recent Highlights - PR Newswire
Geode Capital Management LLC Purchases 8,546 Shares of Aadi Bioscience, Inc. (NASDAQ:AADI) - Defense World
Aadi Bioscience (NASDAQ:AADI) Trading Down 0.6% – Should You Sell? - Defense World
Ten March deals passed $1B, totaling $25.31B in value - BioWorld MedTech
Personalized Medicine Market Forecast Report and Company Analysis 2025-2033 Featuring Abbott, GE, Aadi Bioscience, Illumina, QIAGEN, Eli Lilly and Co, Takeda, AbbVie, F. Hoffmann-La RocheResearchAndMarkets.com | FinancialContent - FinancialContent
Analyzing Aadi Bioscience (NASDAQ:AADI) and Orgenesis (NASDAQ:ORGS) - Defense World
Whitehawk Therapeutics - The Pharma Letter
Aadi Bioscience Reports Interim Results from PRECISION1 Trial of nab-Sirolimus Demonstrating Anti-Tumor Activity in Solid Tumors with TSC1 or TSC2 Inactivating Alterations - MarketScreener
Aadi Bioscience to Participate at Upcoming Investor Conferences - MarketScreener
Aadi Bioscience to Participate in Upcoming Investor Events - MarketScreener
Aadi Bioscience Announces Poster Presentations at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics - MarketScreener
Aadi Bioscience Announces Poster Presentations on Nab-Sirolimus at the International Gynecologic Cancer Society (IGCS) 2023 Annual Global Meeting - MarketScreener
Aadi Bioscience to Present at the TD Cowen 44th Annual Healthcare Conference - MarketScreener
Aadi Bioscience, Inc. Announces First Patient Dosed in its PRECISION 1 Phase 2 Registrational Trial of nab-Sirolimus in Patients with Solid Tumors Harboring Pathogenic Inactivating Alterations in TSC1 and TSC2 Genes - MarketScreener
Earnings Flash (AADI) AADI BIOSCIENCE Posts Q4 Revenue $5.2M - MarketScreener
Aadi Bioscience, (AADI) reports earnings - Quartz
Whitehawk Therapeutics Closes Sale of Aadi Subsidiary to Kaken Pharmaceuticals - citybiz
Whitehawk Therapeutics sells subsidiary for $102.4 million - Investing.com Australia
Whitehawk Therapeutics sells subsidiary for $102.4 million By Investing.com - Investing.com Canada
Whitehawk sells Aadi Subsidiary to Kaken for $100 million - Investing.com
Whitehawk sells Aadi Subsidiary to Kaken for $100 million By Investing.com - Investing.com India
Whitehawk Therapeutics Completes Strategic Transformation With Successful Closing Of Sale Of Aadi Subsidiary To Kaken Pharmaceuticals - Marketscreener.com
Whitehawk Therapeutics Completes Strategic Transformation with Successful Closing of Sale of Aadi Subsidiary to Kaken Pharmaceuticals - The Victoria Advocate
Aadi Bioscience Announces $72.5 Million Private Placement Equity Financing - MarketScreener
Aadi Bioscience Announces Participation in Upcoming September Investor Conferences - MarketScreener
Aadi Bioscience Announces Leadership Transition - MarketScreener
Aadi Bioscience Announces Improved Anti-Tumor Activity of KRAS Inhibitors in Combination with Nab-sirolimus at the 34th EORTC-NCI-AACR Symposium - MarketScreener
Aadi Bioscience, Inc. (NASDAQ:AADI) Q4 2024 Earnings Call Transcript - Insider Monkey
Aadi Bioscience’s Earnings Call: Strategic Shifts and Promising Pipeline - TipRanks
Suvretta Capital Management, LLC Acquires Significant Stake in A - GuruFocus
Aadi Bioscience Announces Approval of All Proposals at Special M - GuruFocus.com
Aadi Bioscience, Inc. Appoints Baiteng Zhao to its Board of Directors - MarketScreener
Aadi Bioscience Announces Financial Results for the First Quarter 2024 and Provides Corporate Update - Marketscreener.com
Aadi Bioscience Announces Financial Results for the Second Quarter 2024 and Provides Corporate Update - Marketscreener.com
HC Wainwright Adjusts Price Target on Aadi Bioscience to $45 From $48, Maintains Buy Rating - MarketScreener
Aadi Bioscience, Inc. Announces CEO Changes - MarketScreener
Aadi Bioscience Presents New Subgroup Analysis of Patients with Advanced Malignant PEComa of Gynecologic Origin Treated with nab-Sirolimus at Society of Gynecologic Oncology (SGO) - Marketscreener.com
Aadi Bioscience to Participate in the Jefferies Healthcare Conference - MarketScreener
Aadi Bioscience Announces Approval of All Proposals at Special Meeting of Stockholders - Marketscreener.com
Aadi Bioscience Inc (AADI) Q4 2024 Earnings Call Highlights: Strategic Transition and Financial ... By GuruFocus - Investing.com Canada
Whitehawk Therapeutics: Strategic Shift and Financial Outlook - TipRanks
Aadi rebrands as Whitehawk Therapeutics in new ADC focus - The Pharma Letter
Aadi Bioscience, Inc. will Change its Name to Whitehawk Therapeutics, Inc -March 19, 2025 at 12:00 am EDT - Marketscreener.com
Aadi Bioscience earnings missed by $0.46, revenue fell short of estimates - Investing.com UK
Aadi Bioscience Inc changes name to Whitehawk Therapeutics -March 18, 2025 at 05:58 pm EDT - Marketscreener.com
Aadi Bioscience Inc changes name to Whitehawk Therapeutics - TradingView
Aadi Bioscience Relaunches as Whitehawk Therapeutics Marking Evolution into ADC Company - PR Newswire
AADI BIOSCIENCE Earnings Preview: Recent $AADI Insider Trading, Hedge Fund Activity, and More - Nasdaq
Aadi Bioscience to Report Fourth Quarter and Full-Year 2024 Results and Corporate Update - BioSpace
Aadi Bioscience Inc Stock (AADI) Financials Data
Revenue
Net Income
Cash Flow
EPS
17.27%
1.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):